The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Tsirkin V.I.

Viatskiĭ gosudarstvennyĭ gumanitarnyĭ universitet, Kirov;
Kazanskiĭ gosudarstvennyĭ meditsinskiĭ universitet

Trukhina S.I.

Vyatka State University, Kirov, Russia

Trukhin A.N.

Vyatka State University, Kirov, Russia

Khlybova S.V.

Kafedra akusherstva i ginekologii Instituta poslediplomnogo obrazovaniia Kirovskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Anisimov K.Yu.

Department of Obstetrics and Gynecology, Faculty of General Medicine, Ural State Medical University, Yekaterinburg, Russia

Oxytocin receptor antagonists and their clinical application

Authors:

Tsirkin V.I., Trukhina S.I., Trukhin A.N., Khlybova S.V., Anisimov K.Yu.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2018;18(5): 16‑22

DOI: 10.17116/rosakush20181805116

Views: 4561

Downloaded: 96

Download PDF (RU)
Contact the author
Table of contents

OXYTOCIN RECEPTOR ANTAGONISTS AND THEIR CLINICAL APPLICATION
OXYTOCIN RECEPTOR ANTAGONISTS AND THEIR CLINICAL APPLICATION

To cite this article:

Tsirkin VI, Trukhina SI, Trukhin AN, Khlybova SV, Anisimov KYu. Oxytocin receptor antagonists and their clinical application. Russian Bulletin of Obstetrician-Gynecologist. 2018;18(5):16‑22. (In Russ.)
https://doi.org/10.17116/rosakush20181805116

 
 
Подписка 2025-2 (Russian Bulletin of Obstetrician-Gynecologist)
 
МСФ на ЯМ
Close metadata
Recommended articles:
The problem of diabetes mellitus in obstetrics. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):25-29
Clinical obse­rvation of successful pregnancy and deli­very of patients with giant placental chorioangioma. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):103-107
Clinical and anamnestic risk factors for the deve­lopment of spontaneous premature birth in Sibe­rian women of Slavic and Tuvan ethnic groups. Russian Bulletin of Obstetrician-Gynecologist. 2024;(4):42-47
Psychological aspe­cts in predicting preterm labor. Russian Bulletin of Obstetrician-Gynecologist. 2024;(5):95-100
Asse­ssment of risk factors for breast cancer deve­lopment in women living in the Sara­tov region. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):100-106
The expe­rience of performing metroplasty at placenta accreta in the Repu­blic of Crimea. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):77-81
MDSC expression analysis as an impo­rtant marker of early deli­very (a rewiew). Russian Journal of Human Reproduction. 2024;(2):74-79
High mobi­lity group protein B1 (HMGB1) and the pote­ntial for inflammation amplification in preeclampsia and threatened preterm labor. Russian Journal of Human Reproduction. 2024;(5):82-88
Comparison of models for prediction of spontaneous preterm birth. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):10-19
Clinical case of successful pregnancy in a patient with ecto­pic ACTH syndrome after radi­cal surgical treatment. Russian Journal of Human Reproduction. 2024;(6):118-123

The review concerns a depiction of oxytocin receptor antagonists that can be used to inhibit uterine contractility during preterm labor (PL) and in vitro fertilization (IVF) and to stop the birthing process for the fetus’s interests. There is mostly information about the peptide oxytocin receptor antagonist atosiban that has been approved for use in Europe, the USA, and Russia. The available data suggest that atosiban is effective as a tocolytic in the above obstetric situations and relatively highly safe for the mother and fetus. The review also contains data on oxytocin receptor antagonists (the peptide antagonist barusiban, the non-peptide antagonist of the retosiban type, etc.) that are being put through preclinical tests.

Keywords:

oxytocin
oxytocin receptors
labor
preterm labor
tocolytics
peptide (atosiban
barusban) and non-peptide (retosiban) oxytocin receptor antagonists

Authors:

Tsirkin V.I.

Viatskiĭ gosudarstvennyĭ gumanitarnyĭ universitet, Kirov;
Kazanskiĭ gosudarstvennyĭ meditsinskiĭ universitet

Trukhina S.I.

Vyatka State University, Kirov, Russia

Trukhin A.N.

Vyatka State University, Kirov, Russia

Khlybova S.V.

Kafedra akusherstva i ginekologii Instituta poslediplomnogo obrazovaniia Kirovskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Anisimov K.Yu.

Department of Obstetrics and Gynecology, Faculty of General Medicine, Ural State Medical University, Yekaterinburg, Russia

List of references:

  1. Obstetrics: National guide. Ed. Ailamazyan EK, Kulakov VI, Radzinskii VE, Savel’eva GM. Moscow: GEOTAR-Media Publ. 2009;1218. (In Russ.)
  2. Vrachnis N, Malamas FM, Sifakis S, Deligeoroglou E, Iliodromiti Z. The oxytocin — oxytocin receptor system and its antagonists as tocolytic agents. International Journal of Endocrinology. 2011;2011:art 350546. PMID: 22190926 PMCID: PMC3235456 https://doi.org/10.1155/2011/350546
  3. Arrowsmith S, Wray S. Oxytocin: its mechanism of action and receptor signalling in the myometrium. Journal of Neuroendocrinology. 2014;26:6:356-369. PMID: 24888645 https://doi.org/10.1111/jne.12154
  4. Alotaibi MF. The response of rat and human uterus to oxytocin from different gestational stages in vitro. General Physiology and Biophysics. 2017;36:1:75-82. PMID: 27787232. https://doi.org/10.4149/gpb_2016022
  5. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiological Reviews. 2001;81:2:629-683. PMID: 11274341 https://doi.org/10.1152/physrev.2001.81.2.629
  6. Kimura T, Ogita K, Kumasawa K, Tomimatsu T, Tsutsui T. Molecular analysis of parturition via oxytocin receptor expression. Taiwanese Journal of Obstetrics and Gynecology. 2013;52:2:165-170. PMID: 23915847 https://doi.org/10.1016/j.tjog.2013.04.004
  7. Yulia A, Johnson MR. Myometrial oxytocin receptor expression and intracellular pathways. Minerva Ginecologica. 2014;66:3:267-280. PMID: 24971782
  8. Szukiewicz D, Bilska A, Mittal TK, Stangret A, Wejman J, Szewczyk G, Pyzlak M, Zamlynski J. Myometrial contractility influences oxytocin receptor (OXTR) expression in term trophoblast cells obtained from the maternal surface of the human placenta. BMC Pregnancy and Childbirth. 2015;15:220. PMID: 26377392 https://doi.org/10.1186/s12884-015-0656-3
  9. Arthur P, Taggart MJ, Mitchell BF. Oxytocin and parturition: a role for increased myometrial calcium and calcium sensitization? Frontiers in Bioscience. 2007;12:619-633. PMID: 17127323 https://doi.org/10.2741/2087
  10. Kim SH, MacIntyre DA, Hanyaloglu AC, Blanks AM, Thornton S, Bennett PR, Terzidou V. The oxytocin receptor antagonist, Atosiban, activates pro-inflammatory pathways in human amnion via G(αi) signalling. Molecular and Cellular Endocrinology. 2016;420:11-23. PMID: 26586210 https://doi.org/10.1016/j.mce.2015.11.012
  11. Gram A, Boos A, Kowalewski MP. Uterine and placental expression of canine oxytocin receptor during pregnancy and normal and induced parturition. Reproduction in Domestic Animals. 2014;49:Suppl 2:41-49. PMID: 24947860 https://doi.org/10.1111/rda.12295
  12. Friebe-Hoffmann U, Baston DM, Hoffmann TK, Chiao JP, Rauk PN. The influence of interleukin-1beta on oxytocin signalling in primary cells of human decidua. Regulatory Peptides. 2007;142:3:78-85. PMID: 17428554 https://doi.org/10.1016/j.regpep.2007.01.012
  13. Fuchs AR, Goeschen K, Husslein P, Rasmussen AB, Fuchs F. Oxytocin and initiation of human parturition. III. Plasma concentrations of oxytocin and 13,14-dihydro-15-keto-prostaglandin F2 alpha in spontaneous and oxytocin-induced labor at term. American Journal of Obstetrics and Gynecology. 1983;147:5:497-502. PMID: 6638091 https://doi.org/10.1016/0002-9378(83)90005-4
  14. Mesiano S, Chan EC, Fitter JT, Kwek K, Yeo G, Smith R. Progesterone withdrawal and estrogen activation in human parturition are coordinated by progesterone receptor A expression in the myometrium. The Journal of Clinical Endocrinology & Metabolism. 2002;87:6:2924-2930. PMID: 12050275 https://doi.org/10.1210/jcem.87.6.8609
  15. Bishop C.V. Progesterone inhibition of oxytocin signaling in endometrium. Frontiers in Neuroscience. 2013;7:art. 138. PMID: 23966904 PMCID: PMC3735988 https://doi.org/10.3389/fnins.2013.00138
  16. Renthal NE, Williams KC, Mendelson CR. MicroRNAs–mediators of myometrial contractility during pregnancy and labour. Nature Reviews Endocrinology. 2013;9:7:391-401. PMID: 23669656 https://doi.org/10.1038/nrendo.2013.96
  17. Mendelson CR. Minireview: fetal-maternal hormonal signaling in pregnancy and labor. Molecular Endocrinology. 2009;23:7:947-954. PMID: 19282364 https://doi.org/10.1210/me.2009-0016
  18. Thota C, Farmer T, Garfield R, Menon R, Al-Hendy A. Vitamin D elicits anti-inflammatory response, inhibits contractile-associated proteins, and modulates Toll-like receptors in human myometrial cells. Reproductive Sciences. 2013;20:4:463-475. PMID: 23012315 https://doi.org/10.1177/1933719112459225
  19. Ivanisević M, Djelmis J, Buković D. Review on prostaglandin and oxytocin activity in preterm labor. Collegium antropologicum. 2001;25:2:687-694. PMID:11811300
  20. Phaneuf S, Europe-Finner GN, Carrasco MP, Hamilton CH, López Bernal A. Oxytocin signalling in human myometrium. Advances in Experimental Medicine and Biology. 1995;395:453-467. PMID: 8713998
  21. Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database of Systematic Reviews. 2014;6:art. CD004452. PMID: 24903678 https://doi.org/10.1002/14651858.CD004452. pub3
  22. van Vliet EO, Boormans EM, de Lange TS, Mol BW, Oudijk MA. Preterm labor: current pharmacotherapy options for tocolysis. Expert Opinion on Pharmacotherapy. 2014;15:6:787-797. PMID: 24533566 https://doi.org/10.1517/14656566.2014.889684
  23. Haram K, Mortensen JH, Morrison JC. Tocolysis for acute preterm labor: does anything work. The Journal of Maternal-Fetal & Neonatal Medicine. 2015;28:4:371-378. PMID: 24990666 https://doi.org/10.3109/14767058.2014.918095
  24. Rozenberg P. Le point sur la tocolyse [A review on tocolysis]. Journal de Gynécologie Obstétrique et Biologie de la Reproduction. 2015;44:8:752-759. PMID: 26142210 https://doi.org/10.1016/j.jgyn.2015.06.015
  25. Lamont CD, Jørgensen JS, Lamont RF. The safety of tocolytics used for the inhibition of preterm labour. Expert Opinion on Drug Safety. 2016;15:9:1163-1173. PMID: 27159501 https://doi.org/10.1080/14740338.2016.1187128
  26. van Vliet EO, Nijman TA, Schuit E, Heida KY, Opmeer BC, Kok M, Gyselaers W, Porath MM, Woiski M, Bax CJ, Bloemenkamp KW, Scheepers HC, Jacquemyn Y, van Beek E, Duvekot JJ, Franssen MT, Papatsonis DN, Kok JH, van der Post JA, Franx A, Mol BW, Oudijk MA. Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. The Lancet. 2016;387(10033):2117-2124. PMID: 26944026 https://doi.org/10.1016/S0140-6736(16)00548-1
  27. Tsatsaris V, Carbonne B, Cabrol D. Atosiban for preterm labour. Drugs. 2004;64:4:375-382. PMID: 14969573 https://doi.org/10.2165/00003495-200464040-00003
  28. Jenkin G. Oxytocin and prostaglandin interactions in pregnancy and at parturition. Journal of Reproduction and Fertility. Supplement. 1992;45:97-111. PMID: 1304035
  29. Pettibone DJ, Guidotti M, Harrell CM, Jasper JR, Lis EV, O’Brien JA, Reiss DR, Woyden CJ, Bock MG, Evans BE. Progress in the development of oxytocin antagonists for use in preterm labor. Advances in Experimental Medicine and Biology. 1995;395:601-612. PMID: 8714024
  30. Douglas AJ, Leng G, Russell JA. The importance of oxytocin mechanisms in the control of mouse parturition. Reproduction. 2002;123: 4:543-552. PMID: 11914117 https://doi.org/10.1530/rep.0.1230543
  31. Akerlund M, Bossmar T, Brouard R, Kostrzewska A, Laudanski T, Lemancewicz A, Serradeil-Le Gal C, Steinwall M. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. British Journal of Obstetrics and Gynaecology. 1999;106:10:1047-1053. PMID:10519430 https://doi.org/10.1111/j.1471-0528.1999.tb08112.x
  32. Bossmar T. Treatment of preterm labor with the oxytocin and vasopressin antagonist Atosiban. Journal of Perinatal Medicine. 1998; 26:6:458-465. PMID: 10224602. https://doi.org/10.1515/jpme.1998.26.6.458
  33. Thornton S, Vatish M, Slater D. Oxytocin antagonists: clinical and scientific considerations. Experimental Physiology. 2001;86:2:297-302. PMID: 11429647. https://doi.org/10.1113/eph8602186
  34. Pierzynski P. Oxytocin and vasopressin V1A receptors as new therapeutic targets in assisted reproduction. Reproductive BioMedicine Online. 2011;22:1:9-16. PMID: 21130036. https://doi.org/10.1016/j.rbmo.2010.09.015
  35. Yamashita K, Kitano T. Molecular evolution of the oxytocin-oxytocin receptor system in eutherians. Molecular Phylogenetics and Evolution. 2013;67:2:520-528. PMID: 23485918. https://doi.org/10.1016/j.ympev.2013.02.017
  36. Akerlund M, Strömberg P, Hauksson A, Andersen LF, Lyndrup J, Trojnar J, Melin P. Inhibition of uterine contractions of premature labour with an oxytocin analogue. Results from a pilot study. British Journal of Obstetrics and Gynaecology. 1987;94:11:1040-1044. PMID: 3322368 https://doi.org/10.1111/j.1471-0528.1987.tb02287.x
  37. Arrowsmith S, Neilson J, Wray S. The combination tocolytic effect of MgSO4 and an oxytocin receptor antagonist in myometrium from singleton and twin pregnancies. American Journal of Obstetrics and Gynecology. 2016;215:6:789.e1-789.e9. PMID: 27555315 https://doi.org/10.1016/j.ajog.2016.08.015
  38. Carvajal JA, Zambrano MJ, Theodor NM, Moreno LE, Olguín TR, Vanhauwaert PS, Rojas NB, Delpiano AM. The synergic in vitro tocolytic effect of nifedipine plus ritodrine on human myometrial contractility. Reproductive Sciences. 2017;24:4:635-640. PMID: 27609401 https://doi.org/10.1177/1933719116667221
  39. Engstrom T, Bratholm P, Christensen NJ, Vilhardt H. Up-regulation of oxytocin receptors in non-pregnant rat myometrium by isoproterenol: effects of steroids. Journal of Endocrinology. 1999;161: 3:403-411. PMID: 10333543 https://doi.org/10.1677/joe.0.1610403
  40. Schmitz T, Cabrol D. Tocolysis. Atosiban, an ocytcin-receptor antagonist. Journal de Gynécologie Obstétrique et Biologie de la Reproduction. 2001;30:3:238-245. PMID: 11397999
  41. López Bernal A. Mechanisms of labour-biochemical aspects. BJOG: An International Journal of Obstetrics & Gynaecology. 2003;110:Suppl 20:39-45. PMID:12763110 https://doi.org/10.1046/j.1471-0528.2003.00023.x
  42. de Heus R, Mulder EJ, Derks JB, Visser GH. Acute tocolysis for uterine activity reduction in term labor: a review. Obstetrical & Gynecological Survey. 2008;63:6:383-388. PMID: 18492294 https://doi.org/10.1097/OGX.b013e31816ff75b
  43. Zingg HH. Vasopressin and oxytocin receptors. Baillière’s Clinical Endocrinology and Metabolism. 1996;10:1:75-96. PMID: 8734452 https://doi.org/10.1016/s0950-351x(96)80314-4
  44. Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: a systematic review. Obstetrics & Gynecology. 1999; 94:5:Pt 2:869-877. PMID: 10546776 https://doi.org/10.1097/00006250-199911001-00043
  45. Coomarasamy A, Knox EM, Gee H, Song F, Khan KS. Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour: a metaanalysis with an indirect comparison of randomised trials. BJOG: An International Journal of Obstetrics and Gynaecology. 2003;110:12:1045-1049. PMID: 14664874 https://doi.org/10.1111/j.1471-0528.2003.03071.x
  46. Kashanian M, Akbarian AR, Soltanzadeh M. Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology & Obstetrics. 2005;91:1:10-14. PMID: 16043178 https://doi.org/10.1016/j.ijgo.2005.06.005
  47. Thornton JG. Maintenance tocolysis. BJOG: An International Journal of Obstetrics & Gynaecology. 2005;112:Suppl 1:118-121. PMID: 15715609 https://doi.org/10.1111/j.1471-0528.2005.00599.x
  48. Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database of Systematic Reviews. 2005;3:art. CD004452. PMID: 16034931 https://doi.org/10.1002/14651858.cd004452.pub2
  49. Giles W, Bisits A. Preterm labour. The present and future of tocolysis. Best Practice & Research Clinical Obstetrics & Gynaecology. 2007;21:5:857-868. PMID: 17459777 https://doi.org/10.1016/j.bpobgyn.2007.03.011
  50. Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. British Medical Journal. 2012;345:art. e6226. PMID: 23048010 https://doi.org/10.1136/bmj.e6226
  51. Gáspár R, Hajagos-Tóth J. Calcium channel blockers as tocolytics: principles of their actions, adverse effects and therapeutic combinations. Pharmaceuticals (Basel). 2013;23:6:689-699. PMID:24276256 https://doi.org/10.3390/ph6060689
  52. Caritis S. Adverse effects of tocolytic therapy. BJOG: An International Journal of Obstetrics & Gynaecology. 2005;112:Suppl 1:74-78. PMID:15715600 https://doi.org/10.1111/j.1471-0528.2005.00590.x
  53. Areia A, Fonseca E, Moura P. Progesterone use after successful treatment of threatened pre-term delivery. Journal of Obstetrics and Gynaecology. 2013;33:7:678-681. PMID: 24127952 https://doi.org/10.3109/01443615.2013.820266
  54. Tsirkin VI, Kolpakov AG. Effect of atosiban on the inhibitory effect of epinephrine in experiments with the myometrium of nonpregnant rats. Biodiagnosis of the state of natural and natural-technogenic systems: Proceedings of the XV All-Russian Scientific and Practical Conference with international participation, December 4-6, 2017. Book 1. Kirov. 2017;284-289. (In Russ.)
  55. Tsirkin VI, Anisimov KYu, Khlybova SV. Beta-adrenoreceptor inhibitory mechanism and its role in the regulation of uterine contractile activity in pregnant women and parturient women (literature review). Ural’skii meditsinskii zhurnal. 2014;4:5-14. (In Russ.)
  56. Nilsson L, Reinheimer T, Steinwall M, Akerlund M. FE 200 440: a selective oxytocin antagonist on the term-pregnant human uterus. BJOG: An International Journal of Obstetrics and Gynaecology. 2003;110:11:1025-1028. PMID: 14592588 https://doi.org/10.1111/j.1471-0528.2003.02540.x
  57. Pierzynski P, Lemancewicz A, Reinheimer T, Akerlund M, Laudanski T. Inhibitory effect of barusiban and atosiban on oxytocin-induced contractions of myometrium from preterm and term pregnant women. Journal of the Society for Gynecologic Investigation. 2004;11:6:384-387. P MID: 15350251 https://doi.org/10.1016/j.jsgi.2004.02.008
  58. Reinheimer TM, Chellman GJ, Resendez JC, Meyer JK, Bee WH. Barusiban, an effective long-term treatment of oxytocin-induced preterm labor in nonhuman primates. Biology of Reproduction. 2006;75:5:809-814. PMID: 16914691 https://doi.org/10.1095/biolreprod.106.053637
  59. Steinwall M, Bossmar T, Brouard R, Laudanski T, Olofsson P, Urban R, Wolff K, Le-Fur G, Akerlund M. The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor. Gynecological Endocrinology. 2005;20:2:104-109. PMID: 15823830 https://doi.org/10.1080/09513590400021144
  60. Thornton S, Goodwin TM, Greisen G, Hedegaard M, Arce JC. The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. American Journal of Obstetrics and Gynecology. 2009;200:6:627.e1-e610. PMID: 19306963 https://doi.org/10.1016/j.ajog.2009.01.015
  61. Reinheimer TM, Bee WH, Resendez JC, Meyer JK, Haluska GJ, Chellman GJ. Barusiban, a new highly potent and long-acting oxytocin antagonist: pharmacokinetic and pharmacodynamic comparison with atosiban in a cynomolgus monkey model of preterm labor. The Journal of Clinical Endocrinology & Metabolism. 2005;90:4:2275-2281. PMID: 15671092 https://doi.org/10.1210/jc.2004-2120
  62. Brouard R, Bossmar T, Fournié-Lloret D, Chassard D, Akerlund M. Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea. BJOG: An International Journal of Obstetrics and Gynaecology. 2000; 107:5:614-619. PMID: 10826575 https://doi.org/10.1111/j.1471-0528.2000.tb13302.x
  63. Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M, Guillon G. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. Journal of Neuroendocrinology. 2012;24:4:609-628. PMID: 22375852 PMCID: PMC3490377 https://doi.org/10.1111/j.1365-2826.2012.02303.x
  64. Boccia ML, Gorsaud AP, Bachevalier J, Anderson KD, Pedersen CA. Peripherally administered non-peptide oxytocin antagonist, L368,899, accumulates in limbic brain areas: a new pharmacological tool for the study of social motivation in non-human primates. Hormones and Behavior. 2007;52:3:344-351. PMID: 17583705 https://doi.org/10.1016/j.yhbeh.2007.05.009
  65. McCafferty GP, Pullen MA, Wu C, Edwards RM, Allen MJ, Woollard PM, Borthwick AD, Liddle J, Hickey DM, Brooks DP, Westfall TD. Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2007;293:1:R299-R305. PMID: 17395790 https://doi.org/10.1152/ajpregu.00057.2007
  66. Serradeil-Le Gal C, Valette G, Foulon L, Germain G, Advenier C, Naline E, Bardou M, Martinolle JP, Pouzet B, Raufaste D, Garcia C, Double-Cazanave E, Pauly M, Pascal M, Barbier A, Scatton B, Maffrand JP, Le Fur G. SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-yridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor. Journal of Pharmacology and Experimental Therapeutics. 2004;309:1:414-424. PMID: 14722330 https://doi.org/10.1124/jpet.103.061200

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.